OncoMatch/Clinical Trials/NCT06370000
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Is NCT06370000 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Oral Azacitidine for acute myeloid leukemia.
Treatment: Oral Azacitidine — Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 wild-type
FLT3 negative AML
Excluded: FLT3 ITD mutation
FLT3 ITD
Excluded: FLT3 tyrosine kinase domain (TKD) mutation
tyrosine kinase domain (TKD) mutation
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: induction and consolidation
have completed induction and consolidation as defined by the treating physician
Cannot have received: oral azacitidine (oral azacitidine)
History of prior therapy with oral azacitidine
Cannot have received: stem cell transplant
Exception: within previous 3 months prior to initiation of study therapy
Stem cell transplant within previous 3 months prior to initiation of study therapy
Lab requirements
Kidney function
creatinine clearance (by cockroft-gault formula) greater than or equal to 29 ml/min
Liver function
total bilirubin and aspartate aminotransferase/ alanine transaminase (ast/alt) ≤ to institutional 2x upper limit of normal (except gilbert's syndrome, which may enroll if < 2x patient's baseline total bilirubin)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify